Oxidative Stress Predicts Post-Surgery Complications in Gastrointestinal Cancer Patients

M. Leimühler, MD1, A. R. Bourgonje, MD2, H. van Goor, PhD3, M. J. E. Campmans-Kuijpers, PhD2, G. H. de Bock, PhD4, and B. L. van Leeuwen, MD, PhD1

1Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 2Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 3Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 4Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

ABSTRACT

Introduction. An excessive perioperative inflammatory reaction can lead to more postoperative complications in patients treated for gastrointestinal cancers. It has been suggested that this inflammatory reaction leads to oxidative stress. The most important nonenzymatic antioxidants are serum free thiols. The purpose of this study was to evaluate whether high preoperative serum free thiol levels are associated with short-term clinical outcomes.

Methods. Blood samples were drawn before, at the end of, and 1 and 2 days after surgery of a consecutive series of patients with gastrointestinal cancer. Serum free thiols were detected using a colorimetric detection method using Ellman’s reagent. Short-term clinical outcomes were defined as 30-day complications (Clavien-Dindo ≥2) and length of hospital stay. Logistic regression was applied to examine the association between serum free thiol levels and short-term patient outcomes.

Results. Eighty-one patients surgically treated for gastrointestinal cancer were included in the study. Median age was 68 (range 26–87) years, and 28% were female. Patients in the lowest tertile of preoperative serum free thiols had a threefold higher risk to develop postoperative complications (odds ratio [OR]: 3.4; 95% confidence interval [CI]:1.1–10.7) and a fourfold higher risk to have an increased length of stay in the hospital (OR 4.0; 95% CI 1.3–12.9) compared with patients in the highest tertile.

Conclusions. Patients with lower preoperative serum free thiol levels, indicating a decrease in extracellular antioxidant capacity and therefore an increase in systemic oxidative stress, are more likely to develop postoperative complications and show a longer in hospital stay than patients with higher serum free thiol levels.

Keywords Oxidative stress · Thiols · Gastrointestinal cancer · Postoperative complications

Oncological surgery forms the cornerstone of treatment in patients with gastrointestinal cancer. However, 14–34% of these patients experience postoperative complications, leading to disability and even death in up to 25% of frail older patients within the first year after surgery.1–3 Moreover, postoperative complications can lead to a prolonged hospital stay, higher readmission rate, and therefore higher healthcare costs.4,5 The identification of risk factors for postoperative complications can help with treatment selection for a patient and offers possibilities to reduce complications. Previous studies have shown that preoperative factors, such as comorbidities, sarcopenia, and obesity, increase the risk of complications.2,6,7 Furthermore, elevated levels of inflammatory markers, such as IL-6, IL-8, and IL-10, before surgery have been associated with postoperative complications.8–11

Excessive systemic inflammation is intimately associated with higher levels of oxidative stress, which is defined as an imbalance between the production of reactive species and the availability of antioxidant substances.12 Due to this
association, systemic markers of oxidative stress might serve as new prognostic biomarkers for postoperative complications. Oxidative stress is defined by a reduction-oxidation (redox) imbalance, which is characterized by an excessive production of reactive species, while antioxidant availability is decreased.\textsuperscript{13–16} A robust and powerful read-out of an individual redox status is the measurement of a patients’ serum or plasma free thiols (R-SH, sulfhydryl compounds).\textsuperscript{15,17–19} These constitute the most important nonenzymatic antioxidants, because they represent an intricate and dynamic redox regulation system, acting as major scavengers of reactive species as well as serving as multimodal redox relays (\textit{redox switches}) by kinetically controlling redox exchange reactions within the \textit{reactive species interactionome} (RSI), culminating into chemical modifications with both short-term and longer-term biological adaptations.\textsuperscript{20,21} Free thiols can easily be measured in patients’ serum or plasma using established colorimetric detection methods.\textsuperscript{22,23} Free thiols have a potent antioxidant capacity, due to their sulfhydryl group (-SH), which enables them to form reversible disulfide bonds with reactive species (RS), thus balancing the effect of oxidative stress.\textsuperscript{14–17,24} A lower antioxidant capacity, or higher levels of oxidative stress, is characterized by reduced levels of serum free thiols.\textsuperscript{25}

Several studies described lower serum free thiol levels in patients with cancer compared with healthy people.\textsuperscript{15,26–30} Lower serum thiol levels have been associated with lower survival rates in some studies.\textsuperscript{15,31} Furthermore, it has been shown that patients experience a decrease in serum thiol levels after a prostate biopsy.\textsuperscript{16} An oncological surgery might deplete the antioxidant capacity of the patients even more, as it is more extensive than a biopsy. Additionally, a patient with an already higher level of oxidative stress might be more prone to complications after oncological surgery. Therefore, the purpose of this study was to evaluate the association between surgery and systemic redox status of patients with gastrointestinal cancers and the association between serum free thiol concentrations and short-term patient outcomes measured by the occurrence of 30-day complications and the length of hospital stay.

METHODS

Study Population

Data for this observational cohort study were prospectively collected in the setting of an observational cohort study conducted in the University Medical Center Groningen (UMCG) as described elsewhere.\textsuperscript{11,32–34} Patients were included from April 2014 till October 2016 following a previously determined study protocol. Eligible for inclusions were all patients, aged 18 years and older, who received elective oncological surgery in the UMCG, regardless of the primary tumor. Excluded were patients with a Karnofsky Performance Score <80 or the inability to provide written, informed consent. In our study, we included a subcohort of all patients with a diagnosis of gastrointestinal cancer that were included in the observational cohort. All patients signed a written, informed consent for the use of their data and plasma samples. The study (trial number NL 45602.042.14) was approved by the Institutional Review Board (IRB) of the UMCG (in Dutch: “Medisch Ethische Toetsingscommissie, METc”) and conducted in accordance with the principles of the Declaration of Helsinki (2013).

Data Collection

Demographics, such as age, sex and body mass index (BMI), Charlson comorbidity, and ASA score were prospectively registered for all patients during the study.\textsuperscript{35,36} In addition, the type of tumor and its treatment has been registered. Treatment registration included the type of surgery and whether patients received neoadjuvant chemotherapy. Complications within 30 days after surgery according to Clavien-Dindo Classification (CDC) and length of hospital stay were prospectively registered.\textsuperscript{37}

Blood Sampling and Biochemical Analysis

Blood samples were drawn in the morning before surgery, at skin closure, and on the first and second postoperative day to illustrate the changes of biomarkers in time. Blood samples were handled as described previously.\textsuperscript{33} All blood samples were directly centrifuged at 2600 \( \times \) \( g \) for 10 min, after which they were stored at a minimum of \(-80\) °C. All blood was analyzed for C-reactive protein (CRP) (lower limit of detection [LLD]: 0.001 \( \mu \)g/ml), interleukin-1β (IL-1β) (LLD: 1.27 pg/ml), IL-6 (LLD: 0.01 pg/ml), IL-10 (LLD: 3.28 pg/ml), IL-12 (LLD: 5.07 pg/ml), and tumor necrosis factor-alpha (TNF-α) (LLD: 6.49 pg/ml). Haemoscan\textsuperscript{6} (Groningen) analyzed all samples in batches (measured in singular) using sandwich enzyme-linked immunosorbent assays (ELISA) technique for interleukins, developed by BioLegend (San Diego, CA) and high sensitivity CRP ELISA (Dakopatts, Glostrup, Denmark) for CRP.

Measurement of Serum Free Thiols

As a read-out for the systemic redox-status of the patient, free thiol levels were determined. Analysis of the serum samples was executed within the UMCG according
to earlier published work. Dilution of serum samples was done using 0.1 M Tris buffer (pH 8.2). The background absorption was measured using a Variskan microplate reader, together with a reference measurement at 630 nm. After that 20 µl of 1.9 nM 5,5’-dithio-bis (2-nitrobenzoic acid) (DTNB, Ellman’s Reagent, CAS-number 69-78-3, Sigma Aldrich Corporation, St. Louis, MO) in 0.1 M of phosphate buffer (pH 7.0) was added to the samples. The samples were incubated for 20 minutes at room temperature, after which absorbance was measured. Parallel measurement of an L-cysteine CAS-number 52-90-4, Fluka Biochemika, Buchs, Switzerland) calibration curve (concentration range from 15.6 M to 1000 M) in 0.1 M Tris/10 mM EDTA (pH 8.2) determined the final concentrations of free thiol groups in the serum.

Endpoints

The primary endpoint was the occurrence of postoperative complications of grade 2 or above according to the Clavien-Dindo classification within 30 days after surgery. The secondary outcome was the length of hospital stay. Preoperative serum free thiol levels were used as main predictor.

Statistical Analysis

Clinical characteristics and baseline demographics were presented as mean plus standard deviation (SD), or in case of nonnormal distributions as median plus interquartile range (IQR) or as proportions n with their percentages (%). Normality testing was performed using Shapiro-Wilk tests. Serum free thiol levels were divided into tertiles and incorporated as categorical predictor in logistic regression analysis. Univariable logistic regression analyses were performed to examine the associations between predictor variables and the occurrence of postoperative complications and the length of hospital stay. Results were expressed as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Following that, multivariable logistic regression analyses were performed to examine the association between predictor variables taking the relevant covariates into account. A linear-regression analysis was performed to estimate whether the postoperative change in serum free thiol levels was influenced by operative blood loss and length of anesthesia. Statistical analyses were performed using IBM SPSS Statistics software package (version 23.0) for Windows (SPSS Inc. Chicago, IL). Data visualization was performed using GraphPad Prism version 7.02 (GraphPad software, San Diego, CA). Two-tailed p-values ≤ 0.05 were considered statistically significant.

RESULTS

Characteristics of Patients

Of the 143 patients who enrolled in the initial study, we included 81 patients with a diagnosis of gastrointestinal cancer. Baseline serum free thiol levels were available of 75 of the 81 patients. Of these patients, 49 (60.5%) were diagnosed with lower gastrointestinal cancer, including colon cancer, rectal cancer, and appendiceal cancer, whereas 32 (39.5%) patients were diagnosed with upper gastrointestinal cancer, including esophageal cancer, gastric cancer, and small intestinal cancer. Patients with the lowest level of baseline serum free thiol levels more often received neoadjuvant chemotherapy and were more likely to have a stage 3–4 tumor. Baseline demographics and clinical characteristics are presented in Table 1.

Postoperative Outcomes

Within 30 days, 34 (42.0%) patients developed complications of Clavien-Dindo Grade 2 or above (Table 2). Two patients experienced a re-admission. Median length of hospital stay was 10 (range 7–15) days.

Changes in Biomarkers

Serum free thiol levels were normally distributed, whereas the other biomarkers showed no normal distribution. Postoperative changes in serum concentrations of free thiols are depicted in Fig. 1. Free thiols decreased directly after surgery. Changes in serum concentrations of other inflammatory markers can be found in supplementary Table 1. A linear regression analysis showed that free thiol levels decreased significantly more in patients with more blood loss (−0.04 for every ml, p < 0.01) and in patients with a longer duration of anesthesia (−0.09 for every min of anesthesia, p < 0.01).

Association of Biomarkers and Short-Term Outcomes

Postoperative Complications To ascertain the effect of free thiols and other predictors on postoperative complications with a CDC ≥ 2, a logistic regression analysis was performed. Results are presented in Table 3. Patients in the lowest tertile of preoperative free thiol levels had an odds ratio of 3.4 (95% CI 1.1–10.7, p = 0.04), and patients in the second tertile had an odds ratio of 1.9 (95% CI 0.6–6.1, p = 0.28) for developing postoperative complications compared with patients in the highest tertile. Multivariable analysis showed an odds ratio of 4.6 (95% CI 0.94–22.1, p = 0.06) and 2.0 (95% CI 0.4–9.2, p = 0.38) for patients in the lowest and second tertile, respectively,
TABLE 1 Patient characteristics for patients with baseline thiol levels above and below the median

| Characteristic                        | Free thiol levels first tertile (172.7–252.3), n = 25 | Free thiol levels second tertile (252.4–295.7), n = 24 | Free thiol levels third tertile (295.8–316.6), n = 26 |
|--------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Age (year)                           | 68 (61.5–73)                                         | 70.5 (53-86)                                         | 67.0 (26-87)                                         |
| Female, n (%)                        | 7 (28.0)                                             | 7 (29.2)                                             | 8 (30.8)                                             |
| Body mass index (kg/m²)              | 27.4 (±3.2)                                          | 26.9 (±3.4)                                          | 25.9 (±2.6)                                          |
| Charlson comorbidity index, n (%)    |                                                      |                                                      |                                                      |
| 2-4                                   | 9 (36.0)                                             | 8 (33.3)                                             | 12 (46.2)                                            |
| 5-9                                   | 16 (64)                                              | 16 (66.6)                                            | 14 (53.8)                                            |
| ASA, n (%)                           |                                                      |                                                      |                                                      |
| I-II                                  | 17 (68)                                              | 17 (70.8)                                            | 21 (80.8)                                            |
| III-IV                                | 8 (32)                                               | 7 (29.2)                                             | 5 (19.2)                                             |
| Primary tumor, n (%)                  |                                                      |                                                      |                                                      |
| Upper GI                              | 14 (56.0)                                            | 5 (20.8)                                             | 9 (34.6)                                             |
| Lower GI                              | 11 (44.0)                                            | 19 (79.2)                                            | 17 (65.4)                                            |
| Neoadjuvant chemotherapy, n (%)       |                                                      |                                                      |                                                      |
| Tumor stadium, n (%)                  |                                                      |                                                      |                                                      |
| I–II                                  | 2 (8.0)                                              | 5 (20.8)                                             | 5 (19.2)                                             |
| III–IV                                | 19 (76.0)                                            | 15 (62.5)                                            | 12 (46.2)                                            |
| Unknown                               | 4 (16.0)                                             | 4 (16.7)                                             | 9 (34.6)                                             |
| Type of surgery                       |                                                      |                                                      |                                                      |
| Laparoscopy                           | 6 (24.0)                                             | 3 (12.5)                                             | 8 (30.8)                                             |
| Laparotomy                            | 19 (76.0)                                            | 21 (87.5)                                            | 18 (69.2)                                            |

GI gastrointestinal tract; Upper GI esophagus, gastric, small intestines; Lower GI colon, rectum, appendix

TABLE 2 Postoperative outcomes

| Complications following Clavien-Dindo, n (%) | 33 (44.0) | 8 (10.7) | 21 (28.0) | 6 (8.0) | 3 (4.0) | 4 (5.3) |
|---------------------------------------------|-----------|---------|----------|--------|--------|-------|

compared with patients in the highest tertile of preoperative free thiols (Table 4).

Length of Stay  Logistic regression showed that patients in the lowest tertile of preoperative free thiol levels had a fourfold risk (OR: 4.0; 95% CI 1.3-12.9, p = 0.01) to have a length of stay above the median compared with patients in the highest tertile (supplementary Table 2).

DISCUSSION

This observational study shows that patients with relatively lower preoperative serum free thiol levels were more likely to develop complications postoperatively and have a fourfold higher odds to have a longer in-hospital stay than

FIG. 1. Development of free thiol levels over time
patients with higher serum free thiol levels. Furthermore, it is demonstrated that serum-free thiol levels decreased directly after surgery without short-term recovery.

Until this date, these associations have not yet been described in the context of gastrointestinal cancer. However, a relationship between lower total thiol levels and lower Karnofsky performance scores, which are known to be related to patient functioning, has been shown. In addition, a study by Topuz et al. showed that patients with lower free thiol levels are more prone to develop chemotherapy-induced cardiac toxicity.

Although there is no literature on the association of serum free thiol levels and complications, an association between lower serum thiol levels and lower survival rates has been described previously. In a study of 3361 patients with colorectal cancer, patients with lower serum total thiols had a higher mortality rate both due to colorectal cancer-related deaths as well as death due to other causes compared with patients with higher levels of serum total thiols. The association of lower serum free thiol levels and a decreased survival also has been described in non-small cell lung cancer patients, hepatic cancer, and oral squamous carcinoma. Also outside of oncology, a lower survival rate and a higher likelihood of graft failure has been described in renal transplant recipients with lower serum free thiols. Furthermore, a higher all-cause mortality has been described for people with lower free thiol levels in the general population. It can be hypothesized that these increased mortality rates are caused by postoperative complications. First, complications can be the direct cause of death of a patient. Second, it has been described that patients with more complications have a lower survival rates than patients without complications. Although the reason for this has not yet been specified, complications may cause a prolonged or incomplete recovery. In addition, it might be impossible to administer necessary adjuvant treatments to a patient with complications. Why some patients have lower thiol levels before surgery remains unclear. This might be due to the presence of the tumor itself, which has been described in colorectal cancer as well as other nongastrointestinal cancers. However, genetic factors or dietary influences might also play a role, but none of these studies has data on thiol levels before the patients diagnosis of cancer, leaving the cause of lower thiol levels unclear. However, we do know that some lifestyle factors influence free thiol levels. Smoking and a

| TABLE 3 Univariate logistic regression analysis for characteristics at baseline and complications grade 2 or more within 30 days after surgery |
|-----------------|-----------------|-----------------|
| **OR (95% CI)** | **p value**     |
| Free thiol      |                 |
| First tertile (172.7–252.3) | 3.4 (1.1–10.7) | 0.04 |
| Second tertile (252.4–295.7) | 1.9 (0.6–6.1) | 0.28 |
| Third tertile (295.8–316.6) | 1              |
| Gender          |                 |
| Female          | 0.79 (0.3–2.1) | 0.64 |
| Male            | 1               |
| Age (year)      |                 |
| ≤70             | 0.96 (0.4–2.4) | 0.96 |
| >70             | 1               |
| BMI             |                 |
| Normal BMI (<25) | 1              |
| Overweight (25-30) | 1.46 (0.4 – 6.4) | 0.62 |
| Obese (>30)     | 2.40 (0.8 – 7.4) | 0.12 |
| Comorbidity     |                 |
| ≤4              | 1               |
| >4              | 1.23 (0.5–3.1) | 0.66 |
| Tumor stadium   |                 |
| I - II          | 1               |
| III - IV        | 1.5 (0.4–5.1) | 0.54 |
| Neoadjuvant chemotherapy |         |
| No              | 1               |
| Yes             | 1.7 (0.7–4.3) | 0.24 |
| Type of surgery |                 |
| Laparascopy     | 1.1 (0.4–3.4) | 0.91 |
| Laparatomy      |                 |

| TABLE 4 Multivariate logistic regression analysis for characteristics at baseline and complications grade 2 or more within 30 days after surgery |
|-----------------|-----------------|-----------------|
| **OR (95% CI)** | **p value**     |
| Free thiol      |                 |
| First tertile (172.7–252.3) | 4.6 (0.94–22.1) | 0.06 |
| Second tertile (252.4–295.7) | 2.0 (0.4–9.2) | 0.38 |
| Third tertile (295.8–316.6) | 1              |
| Gender          |                 |
| Female          | 0.8 (0.2–3.3) | 0.76 |
| Age (year)      |                 |
| >70             | 1.6 (0.4–5.9) | 0.46 |
| BMI             | 1.1 (0.4–3.0 ) | 0.82 |
| Comorbidity     |                 |
| ≤4              | 0.84 (0.2–3.1) | 0.80 |
| Tumor stadium   |                 |
| ≥4              | 1.2 (0.3–5.2) | 0.81 |
| Neoadjuvant chemotherapy |     |
| Yes             | 1.6 (0.4–6.8) | 0.50 |
| Type of surgery |                 |
| Laparatomy      | 1.8 (0.4–7.6) | 0.41 |

OR odds ratio; CI confidence interval; BMI body mass index
higher BMI both have a negative correlation with serum free thiol levels, whereas exercise is positively correlated with serum free thiol levels.\(^{44,46-50}\)

In our study, we observed that serum free thiol levels decreased directly after surgery, which might reflect the patients’ inflammatory reaction leading to oxidative stress as the result of an imbalance between reactive species and antioxidants. Furthermore, our study showed that serum free thiol levels decreased significantly more in patients experiencing more blood loss and in patients with a longer time of anesthesia, reflecting the surgical stress of the patient. Our results are directly in line with earlier findings. One study among 22 men described a decrease in serum free thiols directly after prostate biopsy, which is most likely due to a spike in oxidative stress directly after the procedure.\(^{16}\) Another study described 68 patients who received either elective laparoscopic cholecystectomy or open inguinal femoral hernia repair.\(^{51}\) In both groups, serum native free thiol levels decreased directly after surgery. Although an increase in serum free thiols levels is seen 24 hours after the surgery, it did not reach baseline levels. Anesthetics used during surgery also might lead to an increased oxidative stress during surgery, therefore explaining the lower serum free thiol levels directly after surgery.\(^{52,53}\) Our study shows that the surgery itself poses a direct burden on the antioxidant capacity of a patient. A patient with already low serum free thiol levels preoperatively is left with only a small antioxidant capacity after surgery, due to the postsurgical decrease in serum free thiol levels. A depleted antioxidant capacity cannot counteract oxidative stress sufficiently and might leave the patient more prone to complications.

**Limitations**

Our study has some limitations that warrant recognition. For instance, our study included patients with different kinds of gastrointestinal tumors, which required different types of surgery. Unfortunately, the number of patients was not sufficient to perform a sensitivity analysis according to tumor types. Furthermore, our data did not allow to stratify patients according to lifestyle. Strengths of the present study include, among others, the prospective data collection according to an earlier defined protocol, which allowed us to study the clinical implication and the development of serum free thiol levels prior to and after oncological surgery. To the best of our knowledge, no other study has focused on the association of serum free thiols and postoperative outcomes in patients with gastrointestinal cancer. Therefore, we believe that our study provides novel insights and opportunities for future research.

**Future Perspectives (Clinical Implications)**

Because serum free thiol levels can be relatively easy, reliably, and minimally invasively quantified in patients, measurement of these compounds may be of significant interest to clinicians. A patient’s systemic redox status can provide valuable information for the clinician, when considering the patient’s risks and benefits of a certain procedure. As our study is the first describing the association between serum free thiols and complications after oncological surgery, the applicability of these results has to be validated in future studies. Adding the antioxidant capacity of a patient to the established risk profile of a patient might improve counseling of patients and help to identify the most suitable treatment.

Furthermore, there might be possibilities to raise the antioxidant capacity of a patient to prevent complications after treatment. First, prehabilitation can focus on lifestyle factors, such as exercising, reducing BMI, and supporting a smoke-free life. Second, administration of antioxidants before surgery might be an additional treatment option. In some studies, it has already been attempted to raise the antioxidant capacity by supplementing a patient’s diet, but so far results are disappointing. Several studies failed to demonstrate an improvement of the antioxidant capacity after supplementation.\(^{54,55}\) One mouse model even showed progression of metastasis in lung cancer after vitamin E supplementation.\(^{56}\) In this context, however, it is important to note that exogenous administration of antioxidant substances should be carefully tailored to an individual’s systemic redox status and directed only against pathologically overproduction of reactive species. Interference with physiological redox signaling processes may lead to adverse effects. For instance, single-electron oxidation of thiols (forming thyl radicals) or disturbance of membrane transport signaling processes, which are dependent on disulfides, may occur as adverse effects.\(^{21,57,58}\) It is therefore important to understand the complexity of the whole-body redox status better, making it possible to treat patients based on their redox status.

**CONCLUSIONS**

Our study demonstrates that in patients with gastrointestinal cancer a lower antioxidant capacity, as reflected by serum free thiols, is a risk factor for postsurgical complications and longer in-hospital stay. Moreover, the antioxidant capacity of a patient is affected by the surgery itself, resulting in decreased serum free thiol levels after surgery.
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1245/s10434-022-11412-8.

OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Tominaiga T, Nonaka T, Shiraisi T, et al. Factors related to short-term outcomes and delayed systemic treatment following primary tumor resection for asymptomatic stage IV colorectal cancer.
2. Cosimbra FJF, de Jesus VHF, Franco CP, et al. Predicting overall and major postoperative morbidity in gastric cancer patients. J Surg Oncol. 2019;120(8):1371–8.
3. Dekker JW, Gooiha KS, Bastiaannet E, et al. Cause of death the first year after curative colorectal cancer surgery; a prolonged impact of the surgery in elderly colorectal cancer patients. Eur J Surg Oncol. 2014;40(11):1481–7.
4. Kabir T, Syn NL, Tan ZZZ, et al. Predictors of post-operative complications after surgical resection of hepatocellular carcinoma and their prognostic effects on outcome and survival: a propensity-score matched and structural equation modelling study. Eur J Surg Oncol. 2020;46(9):1756–65.
5. Turgeon MK, Gambou AC, Lee RM, et al. The intersection of age and tumor biology with postoperative outcomes in patients after cytoreductive surgery and HIPEC. Ann Surg Oncol. 2020;27(13):4894–907.
6. Kumar A, Bakkum-Gamez JN, Weaver AL, McGree ME, Cliby WA. Impact of obesity on surgical and oncologic outcomes in ovarian cancer. Gynecol Oncol. 2014;135(1):19–24.
7. Wang H, Yang R, Xu J, Fang K, Abdelrahim M, Chang L. Sarcopenia as a predictor of postoperative risk of complications, mortality and length of stay following gastrointestinal oncological surgery. Ann R Coll Surg Engl. 2021.
8. Boersema GSA, Wu Z, Menon AG, Kleinesnek GJ, Jeekel J, Lange JF. Systemic inflammatory cytokines predict the infectious complications but not prolonged postoperative ileus after colorectal surgery. Mediators Inflamm. 2018;2018:7141342.
9. Kaufmann KB, Heinrich S, Staelhe HF, Bogatyrevay L, Buerkle H, Goebel U. Perioperative cytokine profile during lung surgery predicts patients at risk for postoperative complications: a prospective, clinical study. PLoS ONE. 2018;13(7):e0199807.
10. Kumar A, Torres ML, Cliby WA, et al. Inflammatory and nutritional serum markers as predictors of peri-operative morbidity and survival in ovarian cancer. Anticancer Res. 2017;37(7):3673–7.
11. Plas M, Rotteveel E, Izkaz GJ, et al. Cognitive decline after major oncological surgery in the elderly. Eur J Cancer. 2017;46:394–402.
12. Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020;21(7):363–83.
13. Gerek CL, Tew KD. Redox metabolism and malignancy. Curr Opin Pharmacol. 2010;10(4):362–8.
14. Ozler S, Oztas E, Tokmak A, et al. The association of thiol/disulfide homeostasis and lipid accumulation index with cardiovascular risk factors in overweight adolescents with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2016;84(4):516–23.
15. Dirican N, Dirican A, Sen O, et al. Thiol/disulfide homeostasis: a prognostic biomarker for patients with advanced non-small cell lung cancer? Redox Rep. 2016;21(5):197–203.
16. Tokgoz H, Tas S, Giray O, et al. The change in serum thiol/disulfide homeostasis after transrectal ultrasound guided prostate biopsy. Int Braz J Urol. 2017;43(3):455–61.
17. Eroglu S, Haskul I, Aziz V, et al. Dynamic thiol/disulfide homeostasis in patients with uterine myoma. Eur J Obstet Gynecol Reprod Biol. 2017;216:24–6.
18. Guney T, Kanat IF, Alkan A, et al. Assessment of serum thiol/disulfide homeostasis in multiple myeloma patients by a new method. Redox Rep. 2017;22(6):246–51.
19. Yuan K, Liu Y, Chen HN, et al. Thiol-based redox proteomics in cancer research. Proteomics. 2015;15(2–3):287–99.
20. Cortese-Krott MM, Koning A, Kuhnhle GGC, et al. The reactive species interactome: Evolutionary emergence, biological significance, and opportunities for redox metabolomics and personalized medicine. Antioxid Redox Signal. 2017;27(10):684–712.
21. Bourgonje AR, Feelisch M, Faber KN, Pasch A, Dijkstra G, van Goor H. Oxidative stress and redox-modulating therapeutics in inflammatory bowel disease. Trends Mol Med. 2020;26(11):1034–46.
22. ELLMAN GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70–7.
23. Hu ML, Louie S, Cross CE, Motchink P, Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med. 1993;121(2):257–62.
24. Topuz M, Sen O, Kaplan M, Akkus O, Erel O, Gur M. The role of thiol/disulfide homeostasis in anthracycline associated cardiac toxicity. Int Heart J. 2017;58(1):69–72.
25. Kundu H, Ates I, Kiziluncte E, et al. A novel oxidative stress marker in acute myocardial infarction: thiol/disulfide homeostasis. Am J Emerg Med. 2015;33(11):1567–71.
26. Erel O, Neselioğlu S. A novel and automated assay for thiol/disulfide homeostasis. Clin Biochem. 2014;47(18):326–32.
27. Gao X, Wilsgaard T, Jansen EHJM, et al. Serum total thiol levels and the risk of lung, colorectal, breast and prostate cancer: a prospective case-cohort study. Int J Cancer. 2019.
28. Sonmez MG, Koçanhan B, Deniz CD, et al. Is oxidative stress measured by thiol/disulfide homeostasis status associated with prostate adenocarcinoma? Cent Eur J Immunol. 2018;43(2):174–9.
29. Hanikoglu F, Hanikoglu A, Kucuksayan E, et al. Dynamic thiol/disulfide homeostasis before and after radical prostatectomy in patients with prostate cancer. Free Radic Res. 2016;50(12):S79–84.
30. Leimkuhler M, Bourgonje AR, van Goor H, van Leeuwen BL, de Bock GH. Systemic oxidative stress and antioxidant capacity in cancer patients. J Translationa Sci. 2019;6.
31. Patel BF, Rawal UM, Dave TK, et al. Lipid peroxidation, total antioxidant status, and total thiols levels predict overall survival in patients with oral squamous cell carcinoma. Integr Cancer Ther. 2007;6(4):365–72.
32. Plas M, de Haan JJ, van der Wal-Huisman H, et al. The systemic impact of a surgical procedure in older oncological patients. Eur J Surg Oncol. 2019;45(8):1403–9.
33. Plas M, Rutgers A, van der Wal-Huisman H, et al. The association between the inflammatory response to surgery and
postoperative complications in older patients with cancer: a prospective prognostic factor study. J Geriatr Oncol. 2020.
34. Weerink LBM, van Leeuwen BL, Gemaat SAM, et al. Vitamin status and the development of postoperative cognitive decline in elderly surgical oncologic patients. Ann Surg Oncol. 2018;25(1):231–8.
35. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
36. Doyle DJ, Goyal A, Bansal P, Garmon EH. American society of anesthesiologists classification. In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2021. NBK441940 [bookaccession].
37. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
38. Bourgonje AR, Gabriels RY, de Borst MH, et al. Serum free thiols are superior to fecal calprotectin in reflecting endoscopic disease activity in inflammatory bowel disease. Antioxidants (Basel). 2019. https://doi.org/10.3390/antiox8090351.
39. Mor V, Laliberte L, Morris JN, Wiemann M. The karnofsky performance status scale. an examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002-7.
40. Boakye D, Jansen L, Schöttker B, et al. Blood markers of oxidative stress are strongly associated with poorer prognosis in colorectal cancer patients. Int J Cancer. 2020.
41. Karatas F, Acat M, Sahin S, et al. The prognostic and predictive significance of serum thiols and disulfide levels in advanced non-small cell lung cancer. Aging Male. 2019:1-10.
42. Schwarz C, Fitschek F, Bar-Or D, et al. Inflammatory response and oxidative stress during liver resection. PLoS ONE. 2017;12(10):e0185685.
43. Frenay AS, de Borst MH, Bachtler M, et al. Serum free sulphydryl status is associated with patient and graft survival in renal transplant recipients. Free Radic Biol Med. 2016;99:345–51.
44. Abdulle AE, Bourgonje AR, Kieneker LM, et al. Serum free thiols predict cardiovascular events and all-cause mortality in the general population: a prospective multicenter study. BMC Med. 2020;18(1):130-020-01587-w.
45. Bai Z, Wang J, Wang T, et al. Clinicopathologic parameters associated with postoperative complications and risk factors for tumor recurrence and mortality after tumor resection of patients with colorectal cancer. Clin Transl Oncol. 2018;20(2):176–92.
46. Kim YW, Kim KY. Factors associated with postoperative complications and 1-year mortality after surgery for colorectal cancer in octogenarians and nonagenarians. Clin Interv Aging. 2016;11:689–97.
47. van den Berg I, Coebergh van den Braak RRI, van Vuigt ILA, Ijzermans JNM, Buettner S. Actual survival after resection of primary colorectal cancer: results from a prospective multicenter study. World J Surg Oncol. 2021;19(1):96-021-02207-4.
48. Ates I, Kaplan M, Inan B, et al. How does thiol/disulfide homeostasis change in prediabetic patients? Diabetes Res Clin Pract. 2015;110(2):166–71.
49. Solak I, Cetinkaya CD, Gederet YT, Kozanhan B, Erel O, Eryilmaz MA. Effects of smoking on thiol/disulfide homeostasis. Eur Rev Med Pharmacol Sci. 2018;22(8):2477–82.
50. Gol M, Özlaya B, Yildirim C, Bal R. Regular exercise, overweight/obesity and sedentary lifestyle cause adaptive changes in thiol-disulfide homeostasis. An Acad Bras Cienc. 2019:91(2):e20180547-3765201920180547 (Epub 2019 Apr 25).
51. Polat M, Ozcan O, Sahin L, et al. Changes in thiol-disulfide homeostasis of the body to surgical trauma in laparoscopic cholecystectomy patients. J Laparoendosc Adv Surg Tech A. 2016;26(12):992-6.
52. Kozanhan B, Inanli I, Deniz CD, et al. Dynamic thiol disulphide homeostasis in operating theater personnel exposed to anesthetic gases. Am J Ind Med. 2017;60(11):1003–9.
53. Nekhail M, Kargar-Shouroki F, Mozdaran H, Yousefinejad S, Alipour H, Fardid R. Association between genotoxic properties of inhalation anesthetics and oxidative stress biomarkers. Toxicol Ind Health. 2020;36(6):454–66.
54. Fumeron C, Nguyen-Khoa T, Saltiel C, et al. Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant. 2005;20(9):1874–9.
55. Huang HY, Helzlsouer KJ, Appel LJ. The effects of vitamin C and vitamin E on oxidative DNA damage: results from a randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2000;9(7):647–52.
56. Wiel C, Le Gal K, Ibrahim MX, et al. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. Cell. 2019;178(2):330-45.e22.
57. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-acetylcysteine: a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7(4):355–9.
58. Kalyanaraman B. Thiyl radicals in biological systems: significant or trivial? Biochem Soc Symp. 1995;61:55–63.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.